Drug intelligence / Profile preview

KIN-7136

Development stage: Discontinued
Lead developer: XOMA
Modality: Small Molecules
Administration: Oral

Overview

KIN-7136 is an investigational, next-generation, brain-penetrant small molecule inhibitor of MEK (mitogen-activated protein kinase kinase) developed by Kinnate Biopharma. It was designed to target MAPK-driven advanced solid tumors, specifically focusing on patients with non-small cell lung cancer and those with brain metastases. Although the FDA cleared its Investigational New Drug (IND) application in August 2023 for a Phase 1 trial (KN-3603) as both a monotherapy and in combination with the pan-RAF inhibitor exarafenib, Kinnate Biopharma announced the discontinuation of its development in September 2023 as part of a strategic reprioritization plan.

Targets

MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)

Beyond the preview

Go deeper on KIN-7136.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KIN-7136.

Explore the full profile